SI2794665T1 - Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use - Google Patents

Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use Download PDF

Info

Publication number
SI2794665T1
SI2794665T1 SI201231138T SI201231138T SI2794665T1 SI 2794665 T1 SI2794665 T1 SI 2794665T1 SI 201231138 T SI201231138 T SI 201231138T SI 201231138 T SI201231138 T SI 201231138T SI 2794665 T1 SI2794665 T1 SI 2794665T1
Authority
SI
Slovenia
Prior art keywords
glycosaminoglycan
chemically modified
molecular weight
hours
less
Prior art date
Application number
SI201231138T
Other languages
English (en)
Slovenian (sl)
Inventor
Hans-Peter Ekre
Per-Olov Eriksson
Ulf Lindahl
Erik Holmer
Original Assignee
Dilafor Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48668970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2794665(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dilafor Ab filed Critical Dilafor Ab
Publication of SI2794665T1 publication Critical patent/SI2794665T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SI201231138T 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use SI2794665T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161577223P 2011-12-19 2011-12-19
PCT/SE2012/051433 WO2013095279A1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
EP12858809.2A EP2794665B1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Publications (1)

Publication Number Publication Date
SI2794665T1 true SI2794665T1 (en) 2018-03-30

Family

ID=48668970

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231138T SI2794665T1 (en) 2011-12-19 2012-12-19 Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use

Country Status (28)

Country Link
US (1) US9475888B2 (OSRAM)
EP (1) EP2794665B1 (OSRAM)
JP (2) JP6543467B2 (OSRAM)
KR (1) KR102135485B1 (OSRAM)
CN (1) CN104144950B (OSRAM)
AU (1) AU2012354229B2 (OSRAM)
BR (1) BR112014014454B1 (OSRAM)
CA (1) CA2856492C (OSRAM)
CL (1) CL2014001651A1 (OSRAM)
CO (1) CO7061069A2 (OSRAM)
CY (1) CY1119899T1 (OSRAM)
DK (1) DK2794665T3 (OSRAM)
ES (1) ES2656613T3 (OSRAM)
HR (1) HRP20180124T1 (OSRAM)
HU (1) HUE036523T2 (OSRAM)
IL (1) IL232905A (OSRAM)
LT (1) LT2794665T (OSRAM)
ME (1) ME02994B (OSRAM)
MX (1) MX351104B (OSRAM)
NO (1) NO2904345T3 (OSRAM)
PL (1) PL2794665T3 (OSRAM)
PT (1) PT2794665T (OSRAM)
RS (1) RS56874B1 (OSRAM)
RU (1) RU2617764C2 (OSRAM)
SI (1) SI2794665T1 (OSRAM)
SM (1) SMT201800143T1 (OSRAM)
WO (1) WO2013095279A1 (OSRAM)
ZA (1) ZA201403640B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
AU2013240598A1 (en) * 2012-03-26 2014-10-02 Dilafor Ab Method for treatment of labor arrest
AU2013240597A1 (en) * 2012-03-26 2014-10-16 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
AU2013260209A1 (en) * 2012-05-08 2014-11-20 Dilafor Ab Treatment of postpartum haemorrhage with chemically modified heparin or heparan sulphate and a uterotonic agent
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
CN103788222B (zh) * 2014-01-08 2016-08-31 中国科学院昆明植物研究所 Fuc3S4S取代的低聚糖胺聚糖及其制备方法
BR112016025443A2 (pt) * 2014-04-30 2017-12-12 Agency Science Tech & Res sulfatos de heparano
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
CA3169421A1 (en) 2020-02-17 2021-08-26 Dilafor Ab Tafoxiparin for the treatment of preeclampsia
JP2025514038A (ja) 2022-05-03 2025-05-02 ディラフォール アクチエボラグ タフォキシパリンの新規な医学的使用
EP4272749A1 (en) 2022-05-03 2023-11-08 Dilafor AB New medical use of tafoxiparin
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
JPS63246396A (ja) * 1987-03-31 1988-10-13 Shiseido Co Ltd モノクロ−ナル抗体
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE9002550D0 (sv) * 1990-08-01 1990-08-01 Kabivitrum Ab Heparinfragment
SE9003181D0 (sv) 1990-10-04 1990-10-04 Kabivitrum Ab Use of heparin fraction
US5280016A (en) 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5250519A (en) 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (ja) * 1991-07-26 1993-02-09 Terumo Corp 低分子量ヘパリン誘導体の製造法
AU5442594A (en) * 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
ATE224918T1 (de) * 1995-03-31 2002-10-15 Hamilton Civic Hospitals Res Zusammensetzung zur hemmung der thromboseentstehung
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
JP4203611B2 (ja) 1996-10-15 2009-01-07 生化学工業株式会社 子宮頸管熟化剤
GB9711443D0 (en) * 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
CA2310422A1 (en) * 1997-11-20 1999-06-03 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
DE69931038T2 (de) 1998-02-26 2006-11-23 Seikagaku Corp. Neue polysaccharidderivate, verfahren zu ihrer herstellung und medizinische zusammensetzungen die diese als aktives bestandteil enthalten
US6028061A (en) 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
WO2000006608A1 (en) * 1998-07-31 2000-02-10 Seikagaku Corporation Novel glycosaminoglycan and drug compositions containing the same
JP2002523522A (ja) * 1998-08-26 2002-07-30 ザ コラボレイティブ グループ，リミテッド． 非誘導化水溶性ベータ−（１，３）−グルカンのレセプター
PL353335A1 (en) * 1999-06-30 2003-11-17 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
JP4897991B2 (ja) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ 超低分子量ヘパリン組成物
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
JP4585072B2 (ja) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物
ES2324701T3 (es) * 2000-09-12 2009-08-13 Massachusetts Institute Of Technology Metodos y productos relacionados con heparina de peso molecular bajo.
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
BRPI0613677A2 (pt) 2005-07-22 2011-01-25 Trf Pharma Inc método para tratar doença de célula falsiforme e sequelas da doença de célula falsiforme
JP2009507209A (ja) * 2005-07-22 2009-02-19 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア ヘパリン組成物およびセレクチン阻害
EP2472258A3 (en) * 2006-04-04 2012-11-28 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
EP2019843A2 (en) * 2006-05-25 2009-02-04 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
SG185925A1 (en) * 2007-11-02 2012-12-28 Momenta Pharmaceuticals Inc Non-anticoagulant polysaccharide compositions
WO2009059284A2 (en) 2007-11-02 2009-05-07 Momenta Pharmaceuticals, Inc. Non-anticoagulant polysaccharide compositions
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
JP5758797B2 (ja) 2008-04-04 2015-08-05 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション アルキル化半合成グリコサミノグリカンエーテルならびにその製造および使用方法
EP2411448B1 (en) * 2009-03-27 2013-03-20 Actamax Surgical Materials LLC Polyglycerol aldehydes
US20120183976A1 (en) 2009-04-16 2012-07-19 He Zhou Methods of assessing activity of a polysaccharide composition
WO2011000032A1 (en) 2009-06-30 2011-01-06 Walter And Eliza Hall Institute Of Medical Research Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
AU2010278721A1 (en) * 2009-07-31 2012-02-16 Bayer Healthcare Llc Modified factor IX polypeptides and uses thereof
BR112012015029A2 (pt) * 2009-12-22 2017-06-27 Lifebond Ltd matriz reticulada, método para controlar a formação de uma matriz, método ou matriz, método para vedar um tecido contra vazamento de um fluído corporal, agente hemostático ou vedante cirúrgico, composição para vedar um ferimento, uso da composição, composição para um veículo para entrega localizada de fármaco, composição para engenharia de tecido, e método para modificar uma composição
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
AU2013240597A1 (en) 2012-03-26 2014-10-16 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor
AU2013240598A1 (en) 2012-03-26 2014-10-02 Dilafor Ab Method for treatment of labor arrest

Also Published As

Publication number Publication date
CN104144950A (zh) 2014-11-12
HK1202883A1 (en) 2015-10-09
IL232905A0 (en) 2014-07-31
WO2013095279A1 (en) 2013-06-27
EP2794665A4 (en) 2015-08-26
ZA201403640B (en) 2017-06-28
CO7061069A2 (es) 2014-09-19
CA2856492A1 (en) 2013-06-27
IL232905A (en) 2017-02-28
BR112014014454B1 (pt) 2021-03-09
ME02994B (me) 2018-10-20
PL2794665T3 (pl) 2018-04-30
CA2856492C (en) 2017-01-10
RU2014129816A (ru) 2016-02-20
SMT201800143T1 (it) 2018-05-02
US20150011505A1 (en) 2015-01-08
RU2617764C2 (ru) 2017-04-26
JP2015500388A (ja) 2015-01-05
NO2904345T3 (OSRAM) 2018-07-21
DK2794665T3 (da) 2018-01-29
EP2794665B1 (en) 2017-11-22
LT2794665T (lt) 2017-12-27
JP6543467B2 (ja) 2019-07-10
EP2794665A1 (en) 2014-10-29
BR112014014454A2 (pt) 2017-06-13
CL2014001651A1 (es) 2014-10-10
HRP20180124T1 (hr) 2018-02-23
JP2018111825A (ja) 2018-07-19
PT2794665T (pt) 2018-01-24
US9475888B2 (en) 2016-10-25
KR102135485B1 (ko) 2020-07-17
CN104144950B (zh) 2017-09-05
MX351104B (es) 2017-10-02
ES2656613T3 (es) 2018-02-27
HUE036523T2 (hu) 2018-07-30
AU2012354229A1 (en) 2014-06-05
RS56874B1 (sr) 2018-04-30
CY1119899T1 (el) 2018-06-27
KR20140113652A (ko) 2014-09-24
AU2012354229B2 (en) 2016-12-01
MX2014007122A (es) 2015-03-05

Similar Documents

Publication Publication Date Title
SI2794665T1 (en) Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
SI2794667T1 (en) Low anticoagulant heparins
JP2015500388A5 (OSRAM)
DK173818B1 (da) Heparinderivat
JP5279160B2 (ja) ヘパリンから誘導した多糖の混合物、その製造方法および、それらを含む医薬品組成
Ciancia et al. Overview of anticoagulant activity of sulfated polysaccharides from seaweeds in relation to their structures, focusing on those of green seaweeds
Flórez et al. Algae polysaccharides’ chemical characterization and their role in the inflammatory process
Karmakar et al. Polysaccharides from the brown seaweed Padina tetrastromatica: Characterization of a sulfated fucan
Zhao et al. Preparation of low-molecular-weight polyguluronate sulfate and its anticoagulant and anti-inflammatory activities
CA2457719A1 (en) Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
Muhitdinov et al. Preparation of sodium cellulose sulfate oligomers by free-radical depolymerization
EP1274446A1 (en) Polysaccharidic esters of n-derivatives of glutamic acid
Song et al. Seaweed-derived fucoidans and rhamnan sulfates serve as potent anti-SARS-CoV-2 agents with potential for prophylaxis
CN108912237B (zh) N-脱硫酸化糖胺聚糖的衍生物以及作为药物的用途
JP5053512B2 (ja) 非常に大きい硫酸化度を持つｋ５多糖体のエピマー化誘導体
CN102558392A (zh) 一种高抗FXa、低抗FIIa低分子肝素钠的制备方法
Yu et al. Structure and anti-influenza A (H1N1) virus activity of three polysaccharides from Eucheuma denticulatum
KR102113905B1 (ko) 카르복실화된(carboxylated) 글리코스아미노글리칸 유도체 및 약물로서의 용도
Sun et al. Sulfated polysaccharide heparin used as carrier to load hydrophobic lappaconitine
EP1745705A1 (en) Process for preparing uronic acid oligosaccharides by extrusion
RU2014149230A (ru) Лечение послеродового кровотечения (прк)
TW202135834A (zh) 抗發炎或抗血管生成之醫藥組成物
CN1473836A (zh) 还原端1位为羧基的古罗糖醛酸寡糖及其衍生物
CN115485308B (zh) 制备低分子量肝素的方法以及由此获得的低分子量肝素
KR101104107B1 (ko) 헤파린으로부터 유도된 다당류의 혼합물, 이의 제조방법 및이를 함유하는 약제학적 조성물